Please assess the completion status of the following clinical trial:

Trial Title: Acetylcarnitine and Insulin Sensitivity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~at least three of these~* Relatives with type 2 diabetes~* Age between 40 and 65 years~* Systolic and diastolic pressure ≥ 140 or ≥90 mmHg respectively~* Body mass index ≥25 for men and ≥24 for women~* Triglycerides ≥200 mg/dl~* Serum creatinine ≤1.5 mg/dl, proteinuria ≤ 0.5g/24h~* Capacity to understand the scope and the risks of the study~* written informed consent~Exclusion Criteria:~* Concomitant treatment with steroids, anti-inflammatory and immunosuppressive drug, and any other drug acting on insulin sensitivity and/or insulin secretion, particularly glitazones and other oral hypoglycemic drug~* Treatment with L-acetylcarnitine in the six months before the study~* Previous or concomitant treatment with metformin~* legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the trial.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- L-acetylcarnitine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).